Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Molecular Partners AG ADR (MOLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MOLN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 12.88% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 143.08M USD | Price to earnings Ratio - | 1Y Target Price 10.59 |
Price to earnings Ratio - | 1Y Target Price 10.59 | ||
Volume (30-day avg) 3650 | Beta 0.63 | 52 Weeks Range 3.32 - 12.70 | Updated Date 04/2/2025 |
52 Weeks Range 3.32 - 12.70 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.8 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-06 | When Before Market | Estimate -0.39 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) -1231.73% |
Management Effectiveness
Return on Assets (TTM) -21.44% | Return on Equity (TTM) -33.98% |
Valuation
Trailing PE - | Forward PE 1.78 | Enterprise Value -23286230 | Price to Sales(TTM) 28.79 |
Enterprise Value -23286230 | Price to Sales(TTM) 28.79 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA 1.23 | Shares Outstanding 36874600 | Shares Floating 14882000 |
Shares Outstanding 36874600 | Shares Floating 14882000 | ||
Percent Insiders - | Percent Institutions 9.72 |
Analyst Ratings
Rating 4.33 | Target Price 10.26 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Molecular Partners AG ADR
Company Overview
History and Background
Molecular Partners AG is a clinical-stage biotech company founded in 2004 in Zurich, Switzerland. It focuses on designing and developing a new class of custom-built protein therapeutics called DARPins (Designed Ankyrin Repeat Proteins). They initially focused on ophthalmology and oncology, later expanding into other therapeutic areas. Its ADR began trading in the US at a later date.
Core Business Areas
- DARPin Therapeutics Development: Molecular Partners develops DARPin therapeutics for various diseases, including ophthalmology, oncology, and infectious diseases. Their DARPins are designed to bind to specific targets with high affinity and selectivity.
- Partnerships and Licensing: Molecular Partners collaborates with pharmaceutical companies to develop and commercialize their DARPin therapeutics. These partnerships provide funding and expertise for clinical development and commercialization.
Leadership and Structure
The company is led by a CEO and a management team with expertise in drug development and commercialization. It has a board of directors that provides strategic oversight.
Top Products and Market Share
Key Offerings
- Ensovibep (MP0420): Ensovibep is a DARPin therapeutic developed in collaboration with Novartis for the treatment of COVID-19. While it showed efficacy, its commercialization was impacted by the emergence of new variants. Novartis licensed the exclusive rights to commercialize, but returned them back to Molecular Partners. Market share data is variable due to the changing landscape of COVID-19 treatments. Competitors include Pfizer (Paxlovid) and Merck (Molnupiravir), Gilead (Veklury) and various vaccine providers.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving. Companies are constantly developing new therapies and technologies. It's highly regulated and requires large capital outlays.
Positioning
Molecular Partners is positioned as an innovative biotech company with a unique DARPin technology platform. They focus on developing novel therapeutics in areas with unmet medical needs. Their advantages lie in the unique properties of DARPins, such as their high affinity, selectivity, and manufacturability.
Total Addressable Market (TAM)
The overall market is very large due to a large range of potential applications. Molecular Partners is well positioned with it's novel and proprietary therapeutic platform
Upturn SWOT Analysis
Strengths
- Proprietary DARPin technology platform
- Potential for rapid development of new therapeutics
- Strong intellectual property portfolio
- Strategic partnerships with pharmaceutical companies
Weaknesses
- Reliance on partnerships for funding and commercialization
- Clinical trial risks and regulatory hurdles
- Competition from established pharmaceutical companies
- Limited internal commercialization capabilities
Opportunities
- Expansion of DARPin technology into new therapeutic areas
- Development of novel combination therapies
- Potential for strategic acquisitions or mergers
- Increased demand for innovative therapeutics
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from biosimilars
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
Competitive Landscape
Molecular Partners competes with both large pharmaceutical companies and smaller biotech companies in the development of novel therapeutics. Its advantage lies in its unique DARPin technology platform, but it faces challenges in competing with companies with greater financial resources and established commercial infrastructure.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on clinical milestones and partnership deals. There has been periods of both rapid growth and decline.
Future Projections: Future projections depend on the success of ongoing clinical trials and the ability to secure new partnerships. Analyst estimates should be viewed with caution due to the inherent uncertainty in the biotechnology industry.
Recent Initiatives: Focus on advancing its DARPin pipeline in ophthalmology and oncology, as well as seeking new partnerships and collaborations.
Summary
Molecular Partners AG ADR is a clinical-stage biotech company with a novel DARPin technology platform. While the Ensovibep partnership outcome negatively impacted the company, their technology and ongoing pipeline still may hold promise. The company's success depends on achieving clinical milestones and securing new partnerships to support the development and commercialization of its therapeutics. Investors should closely monitor clinical trial results and financial performance.
Similar Companies
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- News articles
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor. Data is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Molecular Partners AG ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-16 | Co-Founder, CEO, Member of Management Board & Director Dr. Patrick Amstutz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 158 | |
Full time employees 158 | |||
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.